Jeremy Nuttall, MS
Mr. Nuttall joined IPM in 2003 and is responsible for overseeing the preclinical testing (virology, pharmacology, pharmacokinetics and toxicology) of all IPM products. He also led IPM’s development of the dapivirine-maraviroc ring, the first combination microbicide to enter clinical testing, and the DS003 vaginal tablet.
Mr. Nuttall has over 30 years of experience in drug development, beginning his career in the United Kingdom as a toxicologist in contract research organizations where he was responsible for the conduct of a broad range of general toxicology studies. He later worked for Glaxo (now GSK) for eight years in positions of increasing responsibility. Over eight years with Glaxo, he was responsible for: preparing preclinical documentation for clinical trial and marketing authorization regulatory applications worldwide; recruiting, training and managing a preclinical regulatory affairs group in the Philadelphia area; and establishing and managing a group dedicated to the preclinical regulatory support of marketed products.
Mr. Nuttall received a bachelor’s of science degree in marine biology from the University of Newcastle Upon Tyne and a master’s of science degree in applied toxicology from the University of Surrey.